Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2024
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell LymphomaHarper Hubbeling, Doris Leithner, Emily A Silverman, et al.
British Journal of Haematology|May 12, 2024
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profileRoni Shouval, Adam Goldman, Jessica R Flynn, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Transplantation and Cellular Therapy|April 9, 2021
Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older AdultsAsmita Mishra, Jaime M Preussler, Vijaya Raj Bhatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2021
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell TherapyRoni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
Transplantation and Cellular Therapy|October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with LymphomaReid W Merryman, Robert Redd, Erin Jeter, et al.
The Journal of Clinical Investigation|March 23, 2023
Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplantSusan E Prockop, Aisha Hasan, Ekaterina Doubrovina, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
The Journal of Clinical Investigation|September 8, 2020
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantationGunjan L Shah, Susan DeWolf, Yeon Joo Lee, et al.
Pageof 9